AIM ImmunoTech公司宣布，其针对胰腺癌的Duripanc二期临床试验已提前完成患者入组目标。这一进展标志着公司核心候选药物Ampligen在攻克这一难治性癌症的临床开发道路上，迈出了至关重要的一步。该里程碑的达成，为后续评估Ampligen联合标准疗法治疗胰腺导管腺癌的有效性与安全性铺平了道路，加速了其向关键临床节点推进的进程。
AIM ImmunoTech公司宣布，其针对胰腺癌的Duripanc二期临床试验已提前完成患者入组目标。这一进展标志着公司核心候选药物Ampligen在攻克这一难治性癌症的临床开发道路上，迈出了至关重要的一步。该里程碑的达成，为后续评估Ampligen联合标准疗法治疗胰腺导管腺癌的有效性与安全性铺平了道路，加速了其向关键临床节点推进的进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.